FDA Clearance Tracker · P970054
BIOTRIN PARVOVIRUS B19 IGG
Last checked: Nov 19, 2026Latest source record: Aug 6, 1999 (this decision)Source: openFDAMethods & limitations
Decided
Aug 6, 1999
Approved
Time to decision
708 days
Received Aug 28, 1997. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P970054
- Device name
- BIOTRIN PARVOVIRUS B19 IGG
- Applicant
- Diasorin
- Applicant location
- Stillwater, MN
- Received
- Aug 28, 1997
- Decided
- Aug 6, 1999
- Decision
- Approved
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
This device is indicated for: The Biotrin Parvovirus B19 IgG Enzyme Immunoassay is intended for the qualitative detection of IgG antibodies to B19 virus (B19V, previously known as human parvovirus B19) in human serum, lithium heparin, EDTA, and citrated plasma. This test, in conjunction w/the Biotrin Parvovirus B19 IgM Enzyme Immunoassay, may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure with B19V. The results of these assays may be used tomake a serological determination of past, recent, or current infection with B19V. The clinician should consider the results of these assays as presumptive for risk of fetal infection with B19V. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum).
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MYL (ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Diasorin
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260333 · Decided Jun 15, 2026 · 133 days after receipt
Device type: Groups A, C And G Beta-Hemolytic Streptococcus Nucleic Acid Amplification System (PGX) · Laboratory Medicine & Pathology
K260770 · Decided Jun 4, 2026 · 87 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
P250039 · Decided May 7, 2026 · 220 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM (MYM) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.